258 related articles for article (PubMed ID: 30318614)
1. Serum-plasma matched metabolomics for comprehensive characterization of benign thyroid nodule and papillary thyroid carcinoma.
Huang FQ; Li J; Jiang L; Wang FX; Alolga RN; Wang MJ; Min WJ; Ma G; Zhao YJ; Wang SL; Yu Y; Chen X; Zhu D; Zhu J; Wang G; Xia T; Sang JF; Lai MD; Li P; Zhu W; Qi LW
Int J Cancer; 2019 Feb; 144(4):868-876. PubMed ID: 30318614
[TBL] [Abstract][Full Text] [Related]
2. Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer.
Yu S; Liu C; Hou Y; Li J; Guo Z; Chen X; Zhang L; Peng S; Hong S; Xu L; Li X; Liu R; Chen S; Li B; Weng Z; Li Y; Lv W; Yu J; Xiao H
Oncogene; 2022 Apr; 41(17):2422-2430. PubMed ID: 35279704
[TBL] [Abstract][Full Text] [Related]
3. Altered expression of DLG1-AS1 distinguished papillary thyroid carcinoma from benign thyroid nodules.
He T; Wang H; Sun J; Wu J; Gong F; Li S; Wang H; Li Y
BMC Endocr Disord; 2019 Nov; 19(1):122. PubMed ID: 31718630
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics as a potential method for predicting thyroid malignancy in children and adolescents.
Zhou Q; Zhang LY; Xie C; Zhang ML; Wang YJ; Liu GH
Pediatr Surg Int; 2020 Feb; 36(2):145-153. PubMed ID: 31576470
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
6. Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.
Zhang A; Wang C; Lu H; Chen X; Ba Y; Zhang C; Zhang CY
Dis Markers; 2019; 2019():3717683. PubMed ID: 31636734
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing Benign and Malignant Thyroid Nodules and Identifying Lymph Node Metastasis in Papillary Thyroid Cancer by Plasma
Zhang Z; Reiding KR; Wu J; Li Z; Xu X
Front Endocrinol (Lausanne); 2021; 12():692910. PubMed ID: 34248851
[TBL] [Abstract][Full Text] [Related]
8. Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules.
Yu S; Liu X; Zhang Y; Li J; Chen S; Zheng H; Reng R; Zhang C; Chen J; Chen L
Oncotarget; 2016 Dec; 7(51):84165-84177. PubMed ID: 27705935
[TBL] [Abstract][Full Text] [Related]
9. Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma.
Zhang N; Cong X; Zhou D; Guo L; Yuan C; Xu D; Su C
Cancer Biomark; 2019; 24(1):7-17. PubMed ID: 30594915
[TBL] [Abstract][Full Text] [Related]
10. Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing.
Pan Q; Zhao J; Li M; Liu X; Xu Y; Li W; Wu S; Su Z
Carcinogenesis; 2020 Mar; 41(1):18-24. PubMed ID: 31560760
[TBL] [Abstract][Full Text] [Related]
11. Metabolite analysis-aided diagnosis of papillary thyroid cancer.
Chen J; Hu Q; Hou H; Wang S; Zhang Y; Luo Y; Chen H; Deng H; Zhu H; Zhang L; Liu H; Wang A; Liu Y
Endocr Relat Cancer; 2019 Dec; 26(12):829-841. PubMed ID: 31671400
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
13. Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma.
Li M; Song Q; Li H; Lou Y; Wang L
PLoS One; 2015; 10(7):e0132403. PubMed ID: 26168287
[TBL] [Abstract][Full Text] [Related]
14. Cell-free DNA methylation biomarker for the diagnosis of papillary thyroid carcinoma.
Hong S; Lin B; Xu M; Zhang Q; Huo Z; Su M; Ma C; Liang J; Yu S; He Q; Su Z; Li Y; Liu R; Guo Z; Lv W; Xiao H
EBioMedicine; 2023 Apr; 90():104497. PubMed ID: 36868052
[TBL] [Abstract][Full Text] [Related]
15. Plasma metabolites analysis of patients with papillary thyroid cancer: A preliminary untargeted
Razavi SA; Mahmanzar M; Nobakht M Gh BF; Zamani Z; Nasiri S; Hedayati M
J Pharm Biomed Anal; 2024 Apr; 241():115946. PubMed ID: 38241910
[TBL] [Abstract][Full Text] [Related]
16. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma.
Yu S; Liu Y; Wang J; Guo Z; Zhang Q; Yu F; Zhang Y; Huang K; Li Y; Song E; Zheng XL; Xiao H
J Clin Endocrinol Metab; 2012 Jun; 97(6):2084-92. PubMed ID: 22472564
[TBL] [Abstract][Full Text] [Related]
17. Evaluating pre- and post-operation plasma miRNAs of papillary thyroid carcinoma (PTC) patients in comparison to benign nodules.
Rezaei M; Khamaneh AM; Zarghami N; Vosoughi A; Hashemzadeh S
BMC Cancer; 2019 Jul; 19(1):690. PubMed ID: 31307429
[TBL] [Abstract][Full Text] [Related]
18. Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma.
Shi Y; Su C; Hu H; Yan H; Li W; Chen G; Xu D; Du X; Zhang P
PLoS One; 2018; 13(6):e0198896. PubMed ID: 29949618
[TBL] [Abstract][Full Text] [Related]
19. Serum metabolic profiling and features of papillary thyroid carcinoma and nodular goiter.
Yao Z; Yin P; Su D; Peng Z; Zhou L; Ma L; Guo W; Ma L; Xu G; Shi J; Jiao B
Mol Biosyst; 2011 Sep; 7(9):2608-14. PubMed ID: 21713270
[TBL] [Abstract][Full Text] [Related]
20. Plasma Metabolic Profiling of Human Thyroid Nodules by Gas Chromatography-Mass Spectrometry (GC-MS)-Based Untargeted Metabolomics.
Abooshahab R; Hooshmand K; Razavi SA; Gholami M; Sanoie M; Hedayati M
Front Cell Dev Biol; 2020; 8():385. PubMed ID: 32612989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
